showed that compared to the IDH1 wild-type, the intermediate products of glycolysis are significantly reduced in the glioma tissues with IDH1 mutation, which is consistent with our result that risk score is more powerful than IDH mutation after adjusting for some confounders in multivariate analysis (28). This evidence concerns the gene IDH1 and glioma.